Yesterday Dexcom upped the ante in the race for leadership in the expanding CGM space. While terms were not disclosed the acquisition of TypeZero is already paying off as shares of Dexcom continue their surge upward. Yep this company once given up on by almost every analyst is now on a roll. The G6 is off to a great start, CGM adoption continues to increase, they have multiple partners who will drive greater sales and their pipeline is robust.
As we noted yesterday it’s now up to Abbott to respond. Abbott has already indicated they will add features to . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.